Please provide your email address to receive an email when new articles are posted on . Patients showed no difference in skin fibrosis whether they were given low-dose oral glucocorticoids or not. One ...
SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc., announced today the online publication (ahead of print) of the findings from the STAR I trial in Arthritis & Rheumatology Journal, the official journal of ...
Q: My daughter, who is 14-years-old, was diagnosed with localized scleroderma about three years ago, and I am finding out that not much is known on this disease. Could you tell be about it? Does it ...
Patients who underwent autologous stem cell transplantation (ASCT) for diffuse cutaneous systemic sclerosis (dcSSc), also known as scleroderma, did no better than others receiving conventional ...
Pivotal trial to support marketing approval of regenerative cells processed with the Celution® System to commence in Q2 2022 SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc. announced today that the FDA ...
AMSTERDAM — For patients with diffuse cutaneous systemic sclerosis, an autoimmune disease for which there are few treatment options, lenabasum (JBT-101, Corbus Pharmaceuticals) shows potential, new ...
The investigational therapy will be used in Kyverna's KYSA-5 Phase 1/2 open-label, multicenter study to evaluate KYV-101 in adult patients with diffuse cutaneous systemic sclerosis (scleroderma) This ...
MELBOURNE, Australia, Feb. 6, 2023 /PRNewswire/ -- Certa Therapeutics (Certa) today announces ground-breaking clinical trial data for FT011, its novel therapy for the treatment of serious inflammatory ...
The study sample size consisted of 15 patients with early diffuse cutaneous systemic sclerosis -- patients with skin hardening and issues with organs. Of the total participants, 10 patients received 5 ...
The therapy is already being evaluated in patients with lupus nephritis and diffuse cutaneous systemic sclerosis. "We have seen firsthand the transformative effects of KYV-101 in MG patients treated ...
Inflammatory arthritis (IA) occurred in one third of patients with systemic sclerosis (SSc) in a large observational study and was significantly associated with poor quality of life and physical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback